Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Thyrocare Technologies...

    Thyrocare Technologies public offering to raise Rs 480 cr

    Written by savita thakur thakur Published On 2016-04-27T11:18:02+05:30  |  Updated On 27 April 2016 11:18 AM IST
    Thyrocare Technologies public offering to raise Rs 480 cr

    New Delhi : Diagnostics company Thyrocare Technologies will hit the capital markets tomorrow to raise about Rs 480 crore through an initial public offering.


    The company's IPO is scheduled to close on April 29.


    The firm, which runs a diagnostics laboratory chain across the country, will come out with a public issue of up to 10,744,708 equity shares of Rs 10 each for cash.


    These shares would be sold by the company's existing shareholders including A Velumani HUF, Anand Velumani, Sundararaju HUF and Agalia Private Ltd.


    It has fixed a price band of Rs 420 to Rs 446 for the IPO. The company will garner around Rs 479.21 crore at the upper end of the price band.


    Thyrocare competes with diagnostics chains such as Dr Lal PathLabs, SRL Diagnostics, Metropolis Healthcare and Apollo Clinic. It is developing a network of molecular imaging centers for cancer diagnosis.


    After the completion of the offer, the promoters and the promoter group will own approximately 63.96 per cent of equity share.


    The company has proposed to list its shares on both BSE and NSE. The issue is being managed by JM Financial Institutional Securities, Edelweiss Financial Services and ICICI Securities.


    Several healthcare firms like Alkem Laboratories, Dr Lal PathLabs and Narayana Hrudayalaya had hit the capital market last year, while HealthCare Global Enterprises got listed on the stock exchanges last month.

    Agalia PrivateAlkemAnand VelumaniApollocancerDr Lal PathLabsEdelweiss Financial ServicesHUFICICIIPOJM Financial Institutional SecuritiesMetropolis HealthcareNSESRL DiagnosticsSundararaju HUFThyrocare Technologies
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok